---
title: "Second-line therapies-of-renal-cell-carcinoma"
date: "2024-01-03 11:11:04"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ªï¼š[[renal-cell-carcinoma]]

# Second-line therapies-of-renal-cell-carcinoma

- Preferred:
  - Cabozantinib,
  - nivolumab,
  - or lenvatinib+everolimus
- Other options:
  - Any listed in 1st line,
    - everolimus,
    - tivozanib,
    - axitinib+avelumab,
    - sorafenib,
    - or bevacizumab

### Siblings

- [[Epidemiology-of-renal-cell-carcinoma]]
- [[Histology and molecular biology-of-renal-cell-carcinoma]]
- [[Hereditary RCC and germline testing-of-renal-cell-carcinoma]]
- [[Clinical presentation-of-renal-cell-carcinoma]]
- [[Staging (TNM classification) and prognosis-of-renal-cell-carcinoma]]
- [[Treatment principles-of-renal-cell-carcinoma]]
- [[Systemic therapy for metastatic clear cell RCC]]
- [[Second-line therapies-of-renal-cell-carcinoma]]
- [[Combined-modality therapies-of-renal-cell-carcinoma]]
- [[Tyrosine kinase inhibitors-of-renal-cell-carcinoma]]
- [[Immunotherapies-of-renal-cell-carcinoma]]
- [[mTOR inhibitors-of-renal-cell-carcinoma]]
- [[Non-clear cell histology-of-renal-cell-carcinoma]]
